Showing 4341-4350 of 8223 results for "".
- Current Depression, Systemic Inflammation Linked in Psoriasishttps://practicaldermatology.com/news/current-depression-systemic-inflammation-linked-in-psoriasis/2461482/Current depression travels with increased neutrophils in psoriasis patients, especially females, finds research in the Journal of Investigative Dermatology. For the study, re
- Can Harnessing a Tumor’s Power Help Heal Diabetic Foot Ulcers?https://practicaldermatology.com/news/can-harnessing-a-tumors-power-help-heal-diabetic-foot-ulcers/2461480/Scientists may have found a way to train healthy immune cells to accelerate diabetic wound healing. The findings appear in EMBO Molecular Medicine. Diabetic foot ulcers result in
- UCSF Apologizes for Dermatology Experiments in Prisoners in 1960shttps://practicaldermatology.com/news/ucsf-apologizes-for-dermatology-experiments-in-prisoners-in-1960s/2461477/The University of California, San Francisco apologized for conducting unethical dermatology experiments on at least 2,600 incarcerated men in the 1960s and 1970s. Experiments included putting pesticides and herbicides on the men’s skin and injecting it into the
- Practical Dermatology® Magazine’s Sister Publication Named Exclusive Media Partner for Octane’s Aesthetics Tech Forum 2023https://practicaldermatology.com/news/practical-dermatology-magazines-sister-publication-named-exclusive-media-partner-for-octanes-aesthetics-tech-forum-2023/2461474/Practical Dermatology’s sister publication, Modern Aesthetics® magazine, is the exclusive media partner for Octane’s Aesthetics Tech Forum 2023.Now in its fourth year, Octane's Aesthetics Tech Forum is a two-day immersive, in-person and digital
- Journey Medical Corporation Shares Positive Comparative Pharmacokinetic Data for DFD-29 for Rosaceahttps://practicaldermatology.com/news/journey-medical-corporation-shares-positive-comparative-pharmacokinetic-data-for-dfd-29-for-rosacea/2461473/Journey Medical Corporation shared positive PK comparability data of DFD-29 and key updates on the progress of its pivotal Phase 3 clinical study of DFD-29 for the treatment of papulopustular rosacea in collaboration with Dr. Reddy’s Laboratories Ltd. The PK study was designed as
- First Participant Randomized in Dermaliq Therapeutic's Phase 1b/2 Trial Evaluating DLQ01 for AAhttps://practicaldermatology.com/news/first-participant-randomized-in-dermaliq-therapeutics-phase-1b2-trial-evaluating-dlq01-for-aa/2461470/The first participant has been randomized in a Phase 1b/2a trial of Dermaliq Therapeutics Inc.’s DLQ01 solution in men with androgenic alopecia. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ01 in men with and
- Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancerhttps://practicaldermatology.com/news/immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer/2461468/Vaccine exclusively delivered with the PharmaJet Stratis® Needle-free Injection System
- Endo Removes Qwo from Market Due to Concerns About Injection Site Bruising, Skin Discolorationhttps://practicaldermatology.com/news/endo-removes-qwo-from-market-due-to-concerns-about-injection-site-bruising-skin-discoloration/2461467/Endo International plc is ceasing the production and sale of Endo Aesthetics' Qwo (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloratio
- New Melanoma Immunotherapy Drugs Are Saving Liveshttps://practicaldermatology.com/news/new-melanoma-immunotherapy-drugs-are-saving-lives/2461462/New research suggest that the use of new pharmacological therapies is associated with a decrease in the melanoma mortality rate in the U.S. population. In the population-based cross-sectional study of patients with cutaneous melanoma from the Surveillance, Epidemiology, and E
- Hydrafacial, DOCTOR BABOR Collab for New Collagen HA Boosterhttps://practicaldermatology.com/news/hydrafacial-doctor-babor-collab-for-new-collagen-ha-booster/2461461/The Beauty Health Company’s Hydrafacial launched a new booster co-created with BABOR Skincare. The new DOCTOR BABOR Collagen HA booster is inspired by DOCTOR BABOR’s formulations and developed with the BABOR Laboratories in Germany. “Hydrafacial has cre